FHTX

Foghorn Therapeutics Inc

Add to Watchlist

Advanced Chart

4.980

-0.04(-0.797%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.160

Open

4.990

VWAP

4.97

Vol

119.51K

Mkt Cap

281.52M

Low

4.880

Amount

594.00K

EV/EBITDA(TTM)

Total Shares

55.33M

82.85M

EV/OCF(TTM)

P/S(TTM)

12.94

Foghorn Therapeutics Inc. is a clinical-stage, precision therapeutics biotechnology company. The Company is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, it is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is also developing multiple product candidates in oncology. The Gene Traffic Control platform provides an integrated and mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within this system. Its platform enables to produce components of the chromatin regulatory system at scale, thereby allowing to identify these genetic dependencies, understand their mechanism and target their vulnerabilities.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

5.83M

-1.99%

-0.420

+40%

12.16M

+325.83%

-0.307

+2.22%

5.86M

-25%

-0.307

-1.07%

Estimates Revision

The market is revising Upward the revenue expectations for Foghorn Therapeutics Inc. (FHTX) for FY2025, with the revenue forecasts being adjusted by 5.01% over the past three months. During the same period, the stock price has changed by 1.84%.

Revenue Estimates for FY2025

Revise Upward

+5.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.82%

In Past 3 Month

Stock Price

Go Up

+1.84%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast FHTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHTX is 13.00 USD with a low forecast of 13.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.980

Low

13.00

Averages

13.00

High

13.00

Current: 4.980

Low

13.00

Averages

13.00

High

13.00

B. Riley

Yuan Zhi

Buy

maintain

$10

2025-09-17

Reason

B. Riley

Yuan Zhi

Price Target

$10

2025-09-17

maintain

Buy

Reason

B. Riley analyst Yuan Zhi kept a Buy rating on Foghorn Therapeutics with a $10 price target following a transfer of coverage. Foghorn is a clinical-stage biotech company developing targeted oncology therapies that modulate the chromatin regulatory system, the analyst tells investors in a research note. The firm believes investors are ignoring FHD-909's upside potential and anticipates sequential positive reactions following PRT7732's and FHD-909's clinical readouts in late 2025 and early 2026E, respectively.

JMP Securities

Silvan Tuerkcan

Buy

Initiates

2025-04-23

Reason

JMP Securities

Silvan Tuerkcan

Price Target

2025-04-23

Initiates

Buy

Reason

Citizens JMP initiated coverage of Foghorn Therapeutics with an Outperform rating and $9 price target. Foghorn is a clinical-stage biotechnology company focused on developing novel therapies for oncology based on targeting key components of the chromatin regulatory system, the analyst tells investors in a research note. The firm says the company is currently trading at cash, which is an opportunity to pick up a "pharma-backed technology company at a bargain." A leader in chromatin remodeling biology, Foghorn has developed a proprietary Gene Traffic Control platform that enables the determination and validation of genetically determined dependencies, says Citizens.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$13

2025-03-07

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$13

2025-03-07

Reiterates

Strong Buy

Reason

B. Riley Securities

Kalpit Patel

Strong Buy

Initiates

$10

2025-01-30

Reason

B. Riley Securities

Kalpit Patel

Price Target

$10

2025-01-30

Initiates

Strong Buy

Reason

B. Riley initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $10 price target. The firm says its investment thesis centers on the company's strategy to inactivate or degrade SMARCA2 in SMARCA-mutated cancers, "representing a potentially significant market opportunity" accounting for 5% of all solid tumors. The analyst views Foghorn's lead asset, FHD-909, a selective SMARCA2 inhibitor currently in a Phase I dose-escalating study, as the primary value driver. Despite FHD-909's key differentiated attributes and robust preclinical data, the Street is undervaluing the program due to disappointing early efficacy data from Prelude Therapeutics' (PRLD) SMARCA2 degrader, the analyst tells investors in a research note. Riley says the pullback has created an attractive entry point to buy Foghorn shares.

HC Wainwright & Co.

Andrew Fein

Strong Buy

Reiterates

$20 → $13

2024-12-17

Reason

HC Wainwright & Co.

Andrew Fein

Price Target

$20 → $13

2024-12-17

Reiterates

Strong Buy

Reason

Jefferies

Kelly Shi

Strong Buy

Maintains

$18 → $14

2024-12-16

Reason

Jefferies

Kelly Shi

Price Target

$18 → $14

2024-12-16

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Foghorn Therapeutics Inc (FHTX.O) is -3.47, compared to its 5-year average forward P/E of -4.61. For a more detailed relative valuation and DCF analysis to assess Foghorn Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.61

Current PE

-3.47

Overvalued PE

-2.60

Undervalued PE

-6.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.25

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.84

Undervalued EV/EBITDA

-5.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

82.38

Current PS

0.00

Overvalued PS

260.16

Undervalued PS

-95.41

Financials

Annual

Quarterly

FY2025Q2

YoY :

+9.71%

7.56M

Total Revenue

FY2025Q2

YoY :

-12.94%

-21.10M

Operating Profit

FY2025Q2

YoY :

-21.95%

-17.94M

Net Income after Tax

FY2025Q2

YoY :

-37.78%

-0.28

EPS - Diluted

FY2025Q2

YoY :

-17.73%

-21.02M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

+21.00%

-377.82

FCF Margin - %

FY2025Q2

YoY :

-28.86%

-237.34

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

227.6K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

FHTX News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

07:13:01

Foghorn Therapeutics reports Q2 EPS (28c), consensus (32c)

2025-05-14 (ET)

2025-05-14

07:03:29

Foghorn Therapeutics sees cash runway into 2027

2025-05-14

07:03:13

Foghorn Therapeutics reports Q1 EPS (30c), consensus (29c)

News

7.5

08-28PRnewswire

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

5.0

08-11Newsfilter

Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

5.0

07-01Newsfilter

Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

People Also Watch

NWFL

Norwood Financial Corp

Cidara Therapeutics Inc

Angel Oak Mortgage REIT Inc

Hamilton Beach Brands Holding Co

Silence Therapeutics PLC

Benitec Biopharma Inc

13.510

USD

+0.45%

FAQ

What is Foghorn Therapeutics Inc (FHTX) stock price today?

The current price of FHTX is 4.98 USD — it has decreased -0.8 % in the last trading day.

FHTX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

FHTX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Foghorn Therapeutics Inc (FHTX) stock price today?

What is Foghorn Therapeutics Inc (FHTX)'s business?

What is the price predicton of FHTX Stock?

What is Foghorn Therapeutics Inc (FHTX)'s revenue for the last quarter?

What is Foghorn Therapeutics Inc (FHTX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Foghorn Therapeutics Inc (FHTX)'s fundamentals?

How many employees does Foghorn Therapeutics Inc (FHTX). have?

What is Foghorn Therapeutics Inc (FHTX) market cap?